Emerging targets for antidepressant therapies
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Despite adequate antidepressant monotherapy, the majority of depressed patients do not achieve remission. Even optimal and aggressive therapy leads to a substantial number of patients who show minimal and often only transient improvement. In order to address this substantial problem of treatment-resistant depression, a number of novel targets for antidepressant therapy have emerged as a consequence of major advances in the neurobiology of depression. Three major approaches to uncover novel therapeutic interventions are: first, optimizing the modulation of monoaminergic neurotransmission; second, developing medications that act upon neurotransmitter systems other than monoaminergic circuits; and third, using focal brain stimulation to directly modulate neuronal activity. We review the most recent data on novel therapeutic compounds and their antidepressant potential. These include triple monoamine reuptake inhibitors, atypical antipsychotic augmentation, and dopamine receptor agonists. Compounds affecting extra-monoamine neurotransmitter systems include CRF1 receptor antagonists, glucocorticoid receptor antagonists, substance P receptor antagonists, NMDA receptor antagonists, nemifitide, omega-3 fatty acids, and melatonin receptor agonists. Focal brain stimulation therapies include vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS), magnetic seizure therapy (MST), transcranial direct current stimulation (tDCS), and deep brain stimulation (DBS).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059 · cited 1×
“In this study, four patients improved significantly after six months of bilateral DBS targeting the subgenual cingulate white matter [173].”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“Despite adequate care with currently available treatments, up to 70% of depressed patients have residual symptoms [3], and, even with more aggressive therapies, 20% or more may show only a limited response [4].”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
STRESS AND HIPPOCAMPAL PLASTICITY
McEwen, B. S. (1999) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.22.1.105 · Cited by 2,087 · cited 1×
“glutamatergic neurotransmission may play a role in the pathophysiology of depression [83,84], and that stress-induced atrophy of hippocampal neurons in rodents may be attenuated by ionotropic glutamate receptor antagonists [85,86].”
Background(2003) · The Lancet · doi:10.1016/s0140-6736(03)12705-5 · Cited by 1,706
The role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378
Self-citationThe role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“Considerable effort has been targeted to DA circuits based on a growing database implicating DA dysfunction in the pathophysiology of depression [6].”
BackgroundSelf-citationMayberg, H. S. (2003) · British Medical Bulletin · doi:10.1093/bmb/65.1.193 · Cited by 1,166
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 1×
“Despite adequate care with currently available treatments, up to 70% of depressed patients have residual symptoms [3], and, even with more aggressive therapies, 20% or more may show only a limited response [4].”
BackgroundDeep Brain Stimulation to Reward Circuitry Alleviates Anhedonia in Refractory Major Depression
Schlaepfer, T. E., Cohen, M. X., Frick, C., Kosel, M., Brodesser, D., Axmacher, N., Joe, A. Y., Kreft, M., Lenartz, D., & Sturm, V. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301408 · Cited by 1,027 · cited 1×
“Other promising locations include the habenula [180], nucleus accumbens [181], and the thalamic peduncle [182].”
Background
Cited by
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Treadway, M. T., & Zald, D. H. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.006 · Cited by 1,579
“Additionally, studies exploring the effects of glutamatergic compounds in the treatment of depression show promising initial results (McEwen et al. 2010; Rakofsky et al., 2009).”
ResultLinking Molecules to Mood: New Insight Into the Biology of Depression
Krishnan, V., & Nestler, E. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.10030434 · Cited by 643
The neurobiology of depression and antidepressant action
Willner, P., Scheel-Krüger, J., & Belzung, C. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.12.007 · Cited by 519
Alcaro, A., Panksepp, J., Witczak, J., Hayes, D. J., & Northoff, G. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.11.023 · Cited by 144
“corticotropin-releasing factor and substance P) play a key role in the pathophysiology of depression (Nemeroff, 1996; Rakofsky et al., 2009; Thakker-Varia and Alder, 2009); their mechanism of action may include a rebalancing of amino acid neurotransmitter function (Skorzewska et al.”
Thyroid Function Within the Normal Range and the Risk of Depression: A Population-Based Cohort Study
Medici, M., Direk, N., Visser, W. E., Korevaar, T. I. M., Hofman, A., Visser, T. J., Tiemeier, H., & Peeters, R. P. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3589 · Cited by 123
Metadata
- Authors
- Rakofsky, J. J., Holtzheimer, P. E., & Nemeroff, C. B.
- Venue
- Current Opinion in Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 13
- Issue
- 3
- Pages
- 291-302
- ISSN
- 1367-5931 (ISSN-L)
- OpenAlex
- W2027722686
- Cited by
- 72
- References
- 55
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging targets for antidepressant therapies. https://app.cochat.ai/papers/10.1016/j.cbpa.2009.04.617
- The paper
- Rakofsky, J. J., Holtzheimer, P. E., & Nemeroff, C. B. (2009). Emerging targets for antidepressant therapies. Current Opinion in Chemical Biology. https://doi.org/10.1016/j.cbpa.2009.04.617
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.